Johnson & Johnson Family of Companies
1 Johnson & Johnson Plaza
New Brunswick
New Jersey
08933
United States
Tel: 732-524-0400
Fax: 732-524-3300
Website: http://www.jnj.com/
2166 articles with Johnson & Johnson Family of Companies
-
The sealant was developed by Grifols and combines two plasma proteins, fibrinogen and thrombin. The spray is administered with New Jersey-based Ethicon’s airless spray device.
-
The public’s perception of the drug industry can be confusing. Recent studies take a hard look at the industry from different perspectives.
-
Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results - June 18, 2019
6/18/2019
Johnson & Johnson will host a conference call for investors at 8:30 a.m. on Tuesday, July 16th, to review second-quarter results.
-
Clinical Catch-up for June 10-14
6/17/2019
Last week there were quite a few clinical trials whose data were presented. Many were at the American Diabetes Association 79th Scientific Sessions, while others were presented at separate meetings or independently. Here’s a look. -
Global Survey Suggests Gender-Related Barriers Stifle the Leadership Potential of Nurses
6/6/2019
A new report brings together the voices of more than 2,500 nurses and nurse-midwives from 117 different countries on the topic of gender and leadership
-
Hundreds lose their jobs as companies close facilities and shift business focuses.
-
Johnson & Johnson Releases 2018 Health for Humanity Report
6/5/2019
Sharing Progress in Environmental, Social and Governance Practices
-
As the American Society of Clinical Oncology Annual Meeting winds down, here’s a look at some of Monday’s top stories.
-
Johnson & Johnson Celebrates Scientists Across Generations and Geographies with 2019 Dr. Paul Janssen Award for Biomedical Research and Champions of Science® Storytelling Challenge
6/3/2019
Franz-Ulrich Hartl and Arthur Horwich Named 2019 Dr. Paul Janssen Award Winners for Revolutionary Insights into the Fundamental Molecular Process of Protein Folding
-
Phase 3 COLUMBA Study Investigating a Subcutaneous Formulation of DARZALEX® (daratumumab) Showed Non-Inferiority to Intravenous Administration in Patients with Relapsed/Refractory Multiple Myeloma
6/2/2019
New formulation also showed shorter administration time and lower rate of infusion-related reactions
-
DARZALEX® (daratumumab) Investigational Study Shows Increased Depth of Response and Longer Progression-Free Survival in Patients with Newly Diagnosed Multiple Myeloma Who are Eligible for a Transplant
6/2/2019
The Phase 3 CASSIOPEIA study is one of the largest transplant studies ever conducted in multiple myeloma, and the largest study conducted with DARZALEX
-
ERLEADA® (apalutamide) Significantly Improved Overall Survival (OS) and Radiographic Progression-Free Survival (rPFS) in Patients with Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
5/31/2019
Phase 3 results featured in oral presentation at ASCO 2019, selected for Best of ASCO 2019 Meetings, and simultaneously published in The New England Journal of Medicine
-
U.S. FDA Grants Priority Review of INVOKANA® (canagliflozin) sNDA for the Treatment of Chronic Kidney Disease in Patients with Type 2 Diabetes
5/22/2019
The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the U.S. Food and Drug Administration has granted Priority Review for the supplemental New Drug Application for INVOKANA® to reduce the risk of end-stage kidney disease, the doubling of serum creatinine, and renal or cardiovascular death in adults with type 2 diabetes and chronic kidney disease.
-
Andrew Douthwaite, chief technology officer for Colorado-based VirtualArmour, a cybersecurity company, told BioSpace that biotech and pharma companies are desirable targets for hackers and cyber thieves due to the value of the intellectual property.
-
New Data Highlights the Value of SPRAVATO™ (esketamine) CIII Nasal Spray, the First New Antidepressant in Decades that Works Differently for Adults with Treatment-Resistant Depression (TRD)[1]
5/21/2019
The Janssen Pharmaceutical Companies of Johnson & Johnson presented a new cost-efficiency analysis at the International Society for Pharmacoeconomics and Outcomes Research Annual Meeting that illustrates the value of SPRAVATO™ CIII nasal spray for treatment-resistant depression, for patients, U.S. payers, and society.
-
Owlstone Medical Enters into a Strategic Collaboration with Actelion to Develop a Breath-Based Test to Help Facilitate Early Detection of Pulmonary Hypertension
5/20/2019
Owlstone Medical announces a strategic collaboration with Actelion Pharmaceuticals Ltd, one of the Janssen Pharmaceutical Companies of Johnson & Johnson and a global leader in pulmonary arterial hypertension, to discover and validate a breath-based test to help facilitate the early diagnosis of pulmonary hypertension and its subtypes.
-
Auris Health Announces Early Results from First-In-Human Study of Monarch™ Platform
5/20/2019
Ongoing BENEFIT Study of Monarch Platform Indicates Safety, Feasibility and Successful Localization of Lung Nodules in 92% of Cases [20-May-2019] DALLAS , May 20, 2019 /PRNewswire/ -- Auris Health, Inc., part of Johnson & Johnson Medical Devices Companies,* today announced early positive results from an ongoing study designed to evaluate the safety and feasibility
-
New Post-hoc Analysis Shows Adding UPTRAVI® (selexipag) Versus Placebo Improved Long-Term Clinical Outcomes Regardless of Time of Treatment Initiation, and Demonstrated an Even More Pronounced Treatment Effect When Initiated Early
5/20/2019
Actelion presents latest post-hoc analysis from the GRIPHON study - the largest randomized, controlled, outcome trial ever conducted in patients with pulmonary arterial hypertension (PAH) [20-May-2019] ALLSCHWIL, Switzerland , May 20, 2019 /PRNewswire/ -- Actelion Pharmaceuticals Ltd, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, has presented
-
New Real-World Evidence Highlights Need for Interventions to Improve Outcomes for Patients Who Have Been Diagnosed with Major Depressive Disorder (MDD) and Suicide Ideation or Attempt
5/18/2019
Janssen Pharmaceutical Companies of Johnson & Johnson presented new real-world data at the American Psychiatric Association 2019 Meeting which suggest that, among adult patients with major depressive disorder, psychiatric treatment in the year prior to a diagnosis of suicide ideation or attempt is markedly low.
-
Johnson & Johnson Outlines Strategy to Deliver Above-Market Growth at 2019 Pharmaceutical Business Review
5/15/2019
Johnson & Johnson (NYSE: JNJ) will host a meeting with industry analysts to review the strategy of its Janssen Pharmaceutical Companies to deliver above-market, compound annual growth through 2023.